Clinically, breast cancer is categorized by estrogen receptor (ER), progesterone receptor (PR), and HER2 expression into hormone receptor (HR)-positive (~75%), HER2-positive (~10%), and triple-negative breast cancer (TNBC, 10–15%) [2]. Here, ESR1 is linked to triple-negative breast carcinoma.